Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Avidity Biosciences, Inc.
AOC 1044-CS2 (EXPLORE44-OLE) is an open label, extension study to Part B of AOC 1044-CS1 (EXPLORE44). AOC 1044-CS2 is designed to evaluate the long-term safety, tolerability, pharmacokinetics, and exploratory efficacy of AOC 1044.
All participants who enroll in AOC 1044-CS2 will receive active treatment. The treatment period is 2 years with IV dosing every 6 weeks.
Once participants have completed active treatment, they will be followed through a 3-month safety follow-up period. The sponsor may extend active treatment beyond 2 years at a future timepoint.
Age
7–27
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Rollover Participants:
Satisfactorily completed AOC 1044-CS1 (EXPLORE44) as determined by the Investigator and Sponsor
No significant tolerability issues with AOC 1044
De novo Participants:
Aged 7 to 27 years, inclusive, at the time of informed consent
Clinical diagnosis of DMD or clear onset of DMD symptoms at or before the age of 6 years
Confirmation of DMD gene mutation amenable to exon 44 skipping
Weight ≥ 23 kg
Ambulatory or non-ambulatory
* Ambulatory participants: LVEF ≥50% and FVC≥50%
* Non-ambulatory participants: LVEF ≥45% and FVC≥40%
PUL 2.0 entry item A ≥3
If on corticosteroids, stable dose for 30 days before screening and throughout the study
You may not be if
Rollover Participants:
Presence of any new condition or worsening of existing condition that could affect a participant\'s safety or ability to comply with study procedures
De novo Participants:
Serum hemoglobin \< lower limit of normal
Uncontrolled hypertension or diabetes
Prior treatment with any cell or gene therapy
Prior treatment with another exon 44 skipping agent within 6 months prior to informed consent